American Journal of Kidney Diseases
Volume 55, Issue 1 , Pages 113-120 , January 2010

Changes in Hemoglobin Level Distribution in US Dialysis Patients From June 2006 to November 2008

  • David M. Spiegel, MD

      Affiliations

    • Health Sciences Center, University of Colorado, Denver, CO
    • Corresponding Author InformationAddress correspondence to David M. Spiegel, MD, 4545 E 9th Ave, Ste 160, Denver, CO 80220
    • ,
  • Irfan Khan, PhD

      Affiliations

    • Department of Health Economics, Amgen Inc, Thousand Oaks, CA
    • ,
  • Mahesh Krishnan, MD, MPH

      Affiliations

    • Department of Health Economics, Amgen Inc, Thousand Oaks, CA
    • ,
  • Tracy J. Mayne, PhD

      Affiliations

    • Department of Health Economics, Amgen Inc, Thousand Oaks, CA

Received 22 May 2009 ,Accepted 24 September 2009.

References 

  1. Collins AJ, Li S, St. Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001;12:2465–2473
  2. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53–61
  3. Lowrie EG, Huang WH, Lew NL, Liu Y. The relative contribution of measured variables to death risk among hemodialysis patients. In:  Hingman FE editors. Death on Hemodialysis: Preventable or Inevitable. Boston, MA: Kluwer Academic Publishers; 1994;p. 121–141
  4. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10:610–619
  5. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int. 2003;63:1908–1914
  6. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17:1181–1191
  7. Roberts TL, Foley RN, Weinhandl ED, Gilbertson DT, Collins AJ. Anaemia and mortality in haemodialysis patients: interaction of propensity score for predicted anaemia and actual haemoglobin levels. Nephrol Dial Transplant. 2006;21:1652–1662
  8. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease (Results of a phase III multicenter clinical trial). Ann Intern Med. 1989;111:992–1000
  9. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin (Results of a combined phase I and II clinical trial). N Engl J Med. 1987;316:73–78
  10. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990;300:573–578
  11. Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol. 1996;7:763–773
  12. Evans RW, Manninen DL, Garrison LP, et al. The quality of life of patients with end-stage renal disease. N Engl J Med. 1985;312:553–559
  13. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin (Cooperative Multicenter EPO Clinical Trial Group). JAMA. 1990;263:825–830
  14. Laupacis A. Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin (The Canadian Erythropoietin Study Group). Semin Nephrol. 1990;10:11–19
  15. National Kidney Foundation. DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. Am J Kidney Dis. 1997;30(suppl 3):S192–S240
  16. US Renal Data System. USRDS 2008 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2008;
  17. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  18. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  19. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  20. Epogen (epoetin alfa) [prescribing information]. Thousand Oaks, CA: Amgen Inc; 2008;
  21. Aranesp (darbepoetin alfa) [prescribing information]. Thousand Oaks, CA: Amgen Inc; 2008;
  22. National Kidney Foundation. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50:471–530
  23. Centers for Medicare & Medicaid Services. CMS Manual System (Pub 100-04 Medicare Claims Processing. Transmittal 1307). http://www.cms.hhs.gov/Transmittals/Downloads/R1307CP.pdfAccessed January 15, 2009
  24. Lacson E, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003;41:111–124
  25. Chan K, Moran J, Hlatky M, Lafayette R. Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients. Nephrol Dial Transplant. 2009;24:1956–1962
  26. Spiegel DM, Gitlin M, Mayne T. Factors affecting anemia management in hemodialysis patients: a single-center experience. Hemodial Int. 2008;12:336–341
  27. Weiner DE, Miskulin DC, Seefeld K, et al. Reducing versus discontinuing erythropoietin at high hemoglobin levels. J Am Soc Nephrol. 2007;18:3184–3191

 Originally published online as doi:10.1053/j.ajkd.2009.09.024 on November 23, 2009.

PII: S0272-6386(09)01310-9

doi: 10.1053/j.ajkd.2009.09.024

American Journal of Kidney Diseases
Volume 55, Issue 1 , Pages 113-120 , January 2010

Article Tools

* Image Usage & Resolution